Vectura Group PLC (VEC) Insider Andrew Derodra Purchases 82,000 Shares
Vectura Group PLC (LON:VEC) insider Andrew Derodra bought 82,000 shares of the stock in a transaction dated Thursday, September 7th. The stock was purchased at an average price of GBX 90 ($1.16) per share, with a total value of £73,800 ($95,311.89).
Andrew Derodra also recently made the following trade(s):
- On Friday, August 4th, Andrew Derodra bought 135 shares of Vectura Group PLC stock. The stock was purchased at an average price of GBX 111 ($1.43) per share, with a total value of £149.85 ($193.53).
Vectura Group PLC (VEC) traded down 5.32% on Thursday, reaching GBX 89.95. The company had a trading volume of 3,632,741 shares. The stock’s 50-day moving average is GBX 111.15 and its 200-day moving average is GBX 128.11. Vectura Group PLC has a 52 week low of GBX 88.90 and a 52 week high of GBX 166.97. The company’s market capitalization is GBX 609.55 million.
A number of research analysts have recently commented on the company. Numis Securities Ltd restated a “buy” rating and issued a GBX 214 ($2.76) target price on shares of Vectura Group PLC in a research note on Friday, May 12th. J P Morgan Chase & Co lowered their target price on Vectura Group PLC from GBX 240 ($3.10) to GBX 210 ($2.71) and set an “overweight” rating for the company in a research note on Friday, May 12th. N+1 Singer restated a “hold” rating on shares of Vectura Group PLC in a research note on Monday, May 22nd. Peel Hunt restated a “hold” rating and issued a GBX 160 ($2.07) target price on shares of Vectura Group PLC in a research note on Thursday, June 29th. Finally, Shore Capital restated a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Vectura Group PLC has a consensus rating of “Buy” and a consensus price target of GBX 209 ($2.70).
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.